Theresa Matkovits - Dec 20, 2022 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role
Chief Development Officer
Signature
/s/ Keith A. Kucinski, attorney-in fact for Theresa Matkovits
Stock symbol
MTNB
Transactions as of
Dec 20, 2022
Transactions value $
$0
Form type
4
Date filed
12/22/2022, 10:24 AM
Previous filing
Dec 15, 2021
Next filing
Dec 15, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Stock Option (right to Buy) Award $0 +625K $0.00 625K Dec 20, 2022 Common Stock 625K $0.53 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023.